Literature DB >> 28871319

Onset ages of hepatopulmonary syndrome and pulmonary hypertension in patients with biliary atresia.

Takehisa Ueno1, Ryuta Saka2, Yuichi Takama2, Hiroaki Yamanaka2, Yuko Tazuke2, Kazuhiko Bessho3, Hiroomi Okuyama2.   

Abstract

PURPOSE: Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (PoPH) are extrahepatic complications of biliary atresia (BA). Their detection is sometimes delayed, which may result in missed opportunities for liver transplantation. The aim of this study was to determine the onset ages of HPS and PoPH in BA patients.
METHODS: BA patients followed at our institution were identified. Patients visited our clinic for routine blood work, as well as regular electrocardiography, chest X-rays, and arterial blood gas tests. Lung perfusion scintigraphy and cardiac ultrasound were performed to diagnose HPS. Cardiac catheterization was conducted to diagnose PoPH.
RESULTS: The study population consisted of 88 BA patients. The median follow-up duration was 11.6 years (range 0.8-26.0 years). Six patients (6.8%) developed HPS and three patients (3.4%) developed PoPH. The median age of onset of HPS was significantly younger than that of PoPH (HPS: 4 years, PoPH: 15 years, P < 0.019). Two patients (66%) with PoPH died, while all patients with HPS survivied.
CONCLUSION: The onset of HPS was significantly earlier than that of PoPH. The mortality rate was high in patients with PoPH. Teenagers with BA should receive routine cardiac echocardiograms to detect PH in its early stages.

Entities:  

Keywords:  Biliary atresia; Hepatopulmonary syndrome; Liver transplantation; Portopulmonary hypertension

Mesh:

Year:  2017        PMID: 28871319     DOI: 10.1007/s00383-017-4136-x

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  22 in total

1.  Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome.

Authors:  G Martinez-Pallí; J A Barberà; P Taurà; I Cirera; J Visa; R Rodriguez-Roisin
Journal:  J Hepatol       Date:  1999-12       Impact factor: 25.083

2.  Living related liver transplantation for biliary atresia with portopulmonary hypertension: case report.

Authors:  Y Urashima; T Tojimbara; I Nakajima; S Sato; M Nakamura; T Kawase; K Kai; S Fuchinoue; S Teraoka
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

Review 3.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

Review 4.  Current options for management of biliary atresia.

Authors:  Amy Gallo; Carlos O Esquivel
Journal:  Pediatr Transplant       Date:  2013-01-24

5.  Pulmonary hypertension associated with postoperative biliary atresia: report of two cases.

Authors:  H Soh; T Hasegawa; T Sasaki; T Azuma; A Okada; S Mushiake; S Kogaki; T Matsushita; T Harada
Journal:  J Pediatr Surg       Date:  1999-12       Impact factor: 2.545

6.  Plasma endothelin-1 level as a marker reflecting the severity of portal hypertension in biliary atresia.

Authors:  T Hasegawa; T Kimura; T Sasaki; A Okada
Journal:  J Pediatr Surg       Date:  2001-11       Impact factor: 2.545

7.  Long-term postsurgical outcome of biliary atresia.

Authors:  T Okazaki; H Kobayashi; A Yamataka; G J Lane; T Miyano
Journal:  J Pediatr Surg       Date:  1999-02       Impact factor: 2.545

Review 8.  Pulmonary hypertension in chronic liver disease.

Authors:  M S Mandell; B M Groves
Journal:  Clin Chest Med       Date:  1996-03       Impact factor: 2.878

Review 9.  Portopulmonary hypertension: a tale of two circulations.

Authors:  Rohit Budhiraja; Paul M Hassoun
Journal:  Chest       Date:  2003-02       Impact factor: 9.410

10.  Clinical significance of plasma endothelin-1 in patients with chronic liver disease.

Authors:  H Matsumoto; J Uemasu; M Kitano; H Kawasaki
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.